에 대한 최신 뉴스 Amgen (NASDAQ:AMGN) 주식

Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ABBV

AMGN

시장이 불안정하고 혼란스러운 시기에는 많은 투자자들이 배당 수익률이 높은 주식으로 눈을 돌립니다. 이러한 주식은 높은 자유 현금 흐름을 가지고 있으며 주주들에게 높은 배당금을 지급하여 보상을 합니다.

Benzinga 독자들은 애널리스트 주식 등급 페이지를 방문하여 자신이 선호하는 주식에 대한 최신 애널리스트 의견을 검토할 수 있습니다. 트레이더들은 Benzinga의 방대한 애널리스트 등급

월가에서 가장 정확한 분석가들이 주목: 고배당 수익을 창출하는 3개의 헬스케어 주식

AMZN

CSCO

SPDR Dow Jones Industrial Average ETF Trust

NVDA

주식과 옵션을 볼 때 투자자들은 섹터 회전, 실적 강세, 다가오는 촉매제 등 여러 가지 전략을 사용한다. 가치 투자자들은 종종 배당주에서 강력한 실적 강세를 찾는다. 다우존스 산업평균지수에는 배당금을 지급하는 주식이 많이 포함되어 있으며, 꾸준히 배당금을 인상해 온 블루칩 기업들이 많다.

2025년 최대 6.8% 배당을 제공하는 고배당 주식 10선: 다우 지수의 주식

Biotech

Specialty ETFs

Health Care

Politics

ETFs

General

SCHD

슈왑 미국 배당주 ETF(NYSE:SCHD)는 12월에 7% 이상 하락하면서 지난 한 달 동안 1년간 상승폭의 절반 이상을 반납했다. SCHD 펀드가 하락한 이유를 살펴보자.

슈왑 미국 배당주 ETF(SCHD), 12월에 7% 이상 하락한 이유는?

Amgen Inc

RBC Capital analyst Gregory Renza reiterates Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Outperform and maintains $324 price target.

Reiteration

RBC Capital Reiterates Outperform on Amgen, Maintains $324 Price Target

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), noting the company&#8217;s catalyst rich one to two years.
The M&amp;A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36413624/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-pot" target="_blank" rel="noreferrer noopener">trial data of&nbsp;aficamten</a> in December 2023. However, last year,&nbsp;Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) decided to step back from pursuing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616494/cytokinetics-heart-drug-is-a-multi-billion-dollar-opportunity-by-2032-despite-novar" target="_blank" rel="noreferrer noopener">the&nbsp;Cytokinetics deal</a>.
Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also all popped up as potential suitors, though the stock faded from there as a deal never materialized.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>
Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) deal and no <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38992589/heart-disease-focused-cytokinetics-operations-are-on-track-despite-acquisition-unce" target="_blank" rel="noreferrer noopener">mergers or acquisitions</a>.
Investors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today.
Stifel has initiated coverage with a Buy rating and a <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $80</a>. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.
Stifel analyst James Condulis writes Cytokinetics&#8217; aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market.
As the rollout of Bristol Myers Squibb Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM).
While the initial launch is not seen as a negative sign for mavacamten&#8217;s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market.
Cytokinetics appears well-positioned to capitalize on Bristol Myers&#8217; groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard.
Under conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion.
Looking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits.
Price Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43131221/halliburton-faces-mixed-q4-with-north-american-weakness-but-global-gains-and-cash-flow-bolster-optimism" target="_blank" rel="noreferrer noopener">Halliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism</a></li>
</ul>

Analyst Color

Initiation

Movers

CYTK

RPRX

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">prescription drug costs</a>.
These negotiations, mandated by the Inflation Reduction Act, will take place in 2025, with the new prices slated to take effect in 2027.
The selected drugs, used to treat conditions like cancer, diabetes, and asthma, represented approximately $41 billion in Medicare Part D costs between November 2023 and October 2024, accounting for 14% of the program's total expenses.
Under the finalized <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower" rel="noreferrer noopener">guidance</a> for the second negotiation cycle, drug manufacturers have until February 28, 2025, to decide on their participation.
The selected drug list for the second cycle of negotiations is:&nbsp;
<ul>
<li>Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy.</li>
<li>Pfizer Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Ibrance for breast cancer and Xtandi for prostate cancer.</li>
<li>GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Asthma and Chronic obstructive pulmonary disease treatment Trelegy Ellipta and Breo Ellipta.</li>
<li>Teva Pharmaceutical Industries Ltd.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Huntington's disease and Tardive dyskinesia drug Austedo, Austedo XR.</li>
<li>Abbvie Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) irritable bowel syndrome treatment Linzess and depression drug Vraylar.</li>
<li>Bristol-Myers Squibb Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Pomalyst for a type of blood cancer.</li>
<li>Boehringer Ingelheim's lung disease drug Ofev and diabetes med Tradjenta.</li>
<li>AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) cancer drug Calquence</li>
<li>Salix Pharmaceuticals' irritable bowel syndrome drug Xifaxan</li>
<li>Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) diabetes drug Janumet; Janumet XR.</li>
<li>Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) psoriasis drug Otezla</li>
</ul>
CMS will evaluate factors such as the drug's clinical benefit, its role in addressing unmet medical needs, and its impact on specific populations, alongside considerations for research, production, and distribution costs.
The first negotiation cycle in 2023 resulted in agreements for price reductions on 10 drugs, with discounts ranging from 38% to 79% off list prices.
The new prices, effective January 2026, are expected to save $6 billion in prescription drug costs annually and reduce out-of-pocket expenses for Medicare beneficiaries by an <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">estimated $1.5 billion</a>.
Looking ahead, CMS plans to expand the program, selecting up to 15 additional drugs for the third cycle and 20 more in subsequent cycles. The Inflation Reduction Act also introduces an out-of-pocket cap of $2,000 for Medicare Part D enrollees starting in 2025. Approximately 11 million beneficiaries are expected to benefit from the cap, saving a projected $7.2 billion annually.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43055401/schlumberger-posts-strong-q4-results-raises-dividend-and-buybacks-championx-deal-to-strengthen-future-growth" target="_blank" rel="noreferrer noopener">Schlumberger Q4: Earnings Beat, Dividend Boost, Offshore Boom And More</a></li>
</ul>
Image via Shutterstock

Government

Large Cap

Regulations

TEVA

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

The Food and Drug Administration approved Amgen Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Lumakras (sotorasib) in combination with Vectibix (panitumumab) for KRAS G12C-mutated metastatic colorectal cancer (mCRC), who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-<a href="https://www.benzinga.com/pressreleases/25/01/n43055207/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-" target="_blank" rel="noreferrer noopener">based chemotherapy</a>. 
Approval is based on the pivotal Phase 3 CodeBreaK 300 study, which demonstrated that Lumakras plus Vectibix is the first and only targeted treatment combination for chemorefractory KRAS G12C-mutated mCRC to show superior progression-free survival (PFS) compared to the investigated standard-of-care (SOC).
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42189129/amgen-reveals-data-from-closely-watched-monthly-obesity-drug-with-weight-loss-of-up-to-20-at-one-year-and-no-plateau" rel="noreferrer noopener">Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau</a>
The CodeBreaK 300 results demonstrated that Lumakras 960 mg daily plus Vectibix (n=53) showed an improved median progression-free survival (PFS) of 5.6 months compared to 2 months on the investigator&#8217;s choice of care (n=54).
The study demonstrated an&nbsp;improved overall response rate (ORR) of 26% compared to 0% with investigator&#8217;s choice.
The study was not statistically powered for overall survival (OS).&nbsp;The median overall survival (mOS) for patients treated with LUMAKRAS plus Vectibix was not reached, and mOS for patients treated with the investigator&#8217;s choice was 10.3 months, with an HR of 0.7; the final analysis of OS was not statistically significant.&nbsp;
The KRAS G12C mutation is present in approximately 3-5% of colorectal cancers.
Price Action: Amgen stock is up 0.99% at $272.11 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43057606/servicenow-acquires-cuein-to-boost-ai-capabilities" target="_blank" rel="noreferrer noopener">ServiceNow Expands AI Arsenal With Cuein Acquisition: Details</a></li>
</ul>
Image: Shutterstock

FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation

<a href="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html" title="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html">https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html</a>

'Ozempic Is In The Next Round Of Medicare Drug Price Negotiations. See The Full List Of 15 Medications' - CNBC

Amgen Announced FDA Approval Of LUMAKRAS Combined With Vectibix For KRAS G12C-Mutated Metastatic Colorectal Cancer; Phase 3 CodeBreaK 300 Study Showed More Than Doubled Progression-Free Survival (5.6 Months) Compared To SOC (2 Months); Primary Endpoint Met With 26% Overall Response Rate

Investors with a lot of money to spend have taken a bearish stance on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 27% bullish and 63%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $306,375, and 10, calls, for a total amount of $382,064.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $220.0 to $300.0 for Amgen during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 1857.57 with a total volume of 1,376.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $220.0 to $300.0 over the last 30 days.
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736797538_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$14.25</td>
<td>$14.2</td>
<td>$14.25</td>
<td>$260.00</td>
<td>$306.3K</td>
<td align="right">231</td>
<td align="right">109</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$46.0</td>
<td>$44.15</td>
<td>$46.0</td>
<td>$220.00</td>
<td>$73.6K</td>
<td align="right">239</td>
<td align="right">9</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$14.7</td>
<td>$14.35</td>
<td>$14.7</td>
<td>$290.00</td>
<td>$63.2K</td>
<td align="right">60</td>
<td align="right">43</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.3</td>
<td>$3.15</td>
<td>$3.3</td>
<td>$300.00</td>
<td>$40.9K</td>
<td align="right">493</td>
<td align="right">129</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.25</td>
<td>$9.85</td>
<td>$9.85</td>
<td>$290.00</td>
<td>$35.4K</td>
<td align="right">158</td>
<td align="right">94</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Having examined the options trading patterns of Amgen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Amgen</h3>
<ul>
<li>With a trading volume of 1,552,050, the price of AMGN is down by -0.1%, reaching $261.96.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 22 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $296.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Amgen, targeting a price of $280. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Amgen with a target price of $298. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Amgen, maintaining a target price of $310. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Unpacking the Latest Options Trading Trends in Amgen

Amgen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NYSE">AMGN</a>) short percent of float has fallen 3.26% since its last report. The company recently reported that it has 11.17 million shares sold short, which is 2.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Amgen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736790311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amgen has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Amgen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Amgen's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Amgen's Recent Short Interest

Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Equal-Weight and lowers the price target from $335 to $280.

Wells Fargo Maintains Equal-Weight on Amgen, Lowers Price Target to $280

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">investor outlook for 2025</a>.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector&#8217;s performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500&#8217;s 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Ahead of the 2025 JPM Healthcare Conference, JP Morgan highlights some investor expectations as sentiment remains mixed for the US Large Cap BioPharma group heading into 2025. The conference is scheduled between 13 January and 16 January.
Obesity is expected to remain a major focus for the industry. The sector&#8217;s focus on the below advancements highlights the growing importance of obesity treatments and related drug innovations:
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): Increased emphasis on incretin therapies as production capacity grows and direct-to-consumer advertising gains traction. Key data catalysts: Phase 3 results for orforglipron, an oral <a href="https://www.benzinga.com/general/biotech/23/07/33339766/ozempic-alternatives-these-two-drugs-show-promise-in-affordability-and-effectiveness-for-weight-l" target="_blank" rel="noreferrer noopener">small molecule GLP-1</a>.</li>
<li>Initial outcomes data for tirzepatide <a href="https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-" target="_blank" rel="noreferrer noopener">in type 2 diabetes</a>.</li>
</ul>
Several new product launches are on the radar for 2025. Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stands out as a top pick, with the anticipated launch of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">Cobenfy for schizophrenia</a>.
JP Morgan analyst Chris Schott expects a strong adoption once broader insurance coverage, expected by the second half of 2025, is in place.
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is also preparing for a mid-2025 launch of lenacapavir for pre-exposure prophylaxis, with promising uptake <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">projected into 2026</a>.
Additionally, JP Morgan is monitoring Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair for pulmonary arterial hypertension, which has already <a target="_blank" href="https://www.benzinga.com/25/01/42768614/uk-approves-mercks-hypertension-drug-acquired-via-11-billion-acceleron-pharma-deal" rel="noreferrer noopener">exceeded early expectations</a>, and Gilead&#8217;s Livdelzi for primary biliary cholangitis, expected to see more significant growth in 2025 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016935/gilead-unveils-long-term-data-from-seladelpar-in-patients-with-rare-liver-disease" rel="noreferrer noopener">as access improves</a>.
The analyst is watching for updates on how companies are approaching business development after a relatively quiet 2024. While major changes are not anticipated in the size or type of deals pursued by large-cap companies, JP Morgan expects M&amp;A activity to pick up in 2025.
Large deals over $25 billion remain unlikely, with mid-sized deals around $5-15 billion likely to focus on later-stage, lower-risk assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42898400/sanofis-blood-cancer-drugs-new-subcutaneous-formulation-hits-primary-goal-in-late-stage-in-multiple-myeloma" target="_blank" rel="noreferrer noopener">Sanofi&#8217;s Blood Cancer Drug&#8217;s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma</a></li>
</ul>
Image via Shutterstock

GILD

REGN

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) to evaluate etakafusp alfa (formerly known as AB248), Asher Bio's investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA&#xAE; (tarlatamab), Amgen's DLL3-targeting Bispecific T-cell Engager (BiTE&#xAE;) therapy, in patients with extensive-stage small cell lung cancer (ES-SCLC).

Contracts

Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer

Truist Securities analyst Robyn Karnauskas maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Hold and lowers the price target from $333 to $298.

Truist Securities Maintains Hold on Amgen, Lowers Price Target to $298

On Monday, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) granted a conditional marketing authorization to Amgen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Imdylltra for extensive-stage small cell lung cancer with disease progression on or after at least <a href="https://www.benzinga.com/topic/cancer">two prior lines of therapy.</a>
Small cell lung cancer is an aggressive lung cancer subtype that accounts for approximately 15% of lung cancers.
ES-SCLC is characterized by rapid tumor growth and metastatic spread.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42189129/amgen-reveals-data-from-closely-watched-monthly-obesity-drug-with-weight-loss-of-up-to-20-at-one-year-and-no-plateau" rel="noreferrer noopener">Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau</a>
Patients with SCLC are often diagnosed after the cancer has reached an advanced stage because symptoms do not typically appear early in the disease.
"The MHRA's granting of a conditional marketing authorization for tarlatamab is a significant step forward for people living with small cell lung cancer. More than 34,000 people die from lung cancer in the UK each year," said Tony Patrikios, executive medical director, Amgen UK &amp; Ireland.
The conditional marketing authorization is <a target="_blank" href="https://www.businesswire.com/news/home/20241211235493/en/" rel="noreferrer noopener">based</a> on results from the Phase 2 DeLLphi-301 study, which evaluated tarlatamab in patients with ES-SCLC who had failed two or more prior lines of treatment.
Results from the study found that tarlatamab at the 10 mg every two weeks dose (N=99) demonstrated an objective response rate of 41% and a median duration of response of 9.7 months.
Price Action: AMGN stock is down 0.12% at $260.75 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42813592/ai-chip-stocks-nvidia-broadcom-amd-taiwan-semi-micron-super-micro-surge-on-monday-whats-going-on" target="_blank" rel="noreferrer noopener">AI Chip Stocks Nvidia, Broadcom, AMD, Taiwan Semi, Micron, Super Micro Surge Premarket: Whats Going On?</a></li>
</ul>
Photo: Shutterstock

Eurozone

UK Greenlights Amgen's Drug For Aggressive Lung Cancer In Pretreated Patients

Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to IMDYLLTRA&#xAE; for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy, including platinum-based chemotherapy.1
Small cell lung cancer (SCLC) is an aggressive lung cancer subtype that accounts for approximately 15% of lung cancers.3 ES-SCLC is characterised by rapid tumour growth and metastatic spread.5 Patients with SCLC are often diagnosed after the cancer has reached an advanced stage because symptoms do not typically appear early in the disease.6
"The MHRA's granting of a conditional marketing authorisation for tarlatamab is a significant step forward for people living with small cell lung cancer. More than 34,000 people die from lung cancer in the UK each year.2 There is a vital need for novel treatments, particularly for the extensive stage of small cell lung cancer, where outcomes are especially poor," said Tony Patrikios, Executive Medical Director, Amgen UK &amp; Ireland. "This licence brings us one step closer to offering a new treatment option to eligible patients."
The conditional marketing authorisation is based on results from the Phase 2 open label, multicentre study DeLLphi-301, which evaluated tarlatamab in patients with ES-SCLC who had failed two or more prior lines of treatment.4 Results from the study found that tarlatamab at the 10 mg every two weeks (Q2W) dose (N=99) demonstrated an objective response rate (ORR) of 41% (95% Confidence Interval [CI]: 32 to 52) and a median duration of response (DoR) of 9.7 months (range: 5.9, not estimable [NE]).1

Amgen's IMDYLLTRA Approved in UK for Advanced Small Cell Lung Cancer Treatment

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</h3>
<ul>
<li>Dividend Yield: 3.67%</li>
<li>Piper Sandler analyst David Amsellem maintained an Overweight rating and cut the price target from $344 to $310 on Jan. 2. This analyst has an accuracy rate of 66%.</li>
<li>B of A Securities analyst Tim Anderson reinstated an Underperform rating with a price target of $256 on Dec. 10. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Dec. 10, Amgen increased its first-quarter dividend by 6% from $2.25 to $2.38 per share.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">latest AMGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png" alt="" class="wp-image-716759" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-768x705.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>Dividend Yield: 3.66%</li>
<li>B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $191 on Dec. 10. This analyst has an accuracy rate of 63%.</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $206 on Nov. 22. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On Dec. 13, AbbVie announced plans to acquire Nimble Therapeutics.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">latest ABBV news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png" alt="" class="wp-image-716760" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-768x709.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 6.02%</li>
<li>Deutsche Bank analyst George Hill upgraded the stock from Hold to Buy with a price target of $66 on Dec. 3. This analyst has an accuracy rate of 60%.</li>
<li>Truist Securities analyst David Macdonald reiterated a Buy rating and lowered the price target from $76 to $67 on Nov. 20. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: The DOJ recently alleged that CVS violated the Controlled Substances Act by filling unlawful prescriptions for opioid combinations and excessive quantities since 2013.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">CVS stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png" alt="" class="wp-image-716761" style="width:584px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-768x712.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Acuity Brands Stock Ahead Of Q1 Earnings</a></li>
</ul>

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $341.18, a high estimate of $405.00, and a low estimate of $256.00. A decline of 3.38% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1735819208_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Amgen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$344.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$256.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$335.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Buy</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$326.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Yaron Weber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$383.00</td>
<td>$381.00</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$380.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$333.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Amgen. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amgen compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Amgen's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Amgen's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AMGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amgen analyst ratings.</a>
<h2>Discovering Amgen: A Closer Look</h2>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Key Indicators: Amgen's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Amgen's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 23.18%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Amgen's net margin is impressive, surpassing industry averages. With a net margin of 33.28%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Amgen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 42.08% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Amgen's ROA excels beyond industry benchmarks, reaching 3.11%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 8.02, Amgen faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Amgen's Future

Piper Sandler analyst Christopher Raymond maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Overweight and lowers the price target from $344 to $310.

Piper Sandler Maintains Overweight on Amgen, Lowers Price Target to $310

Investors have many strategies when looking at stocks and options, including sector rotation, earnings strength and upcoming catalysts. Value investors often look for strong earnings strength <a href="https://www.benzinga.com/topic/dividend-stocks">from dividend stocks.</a>
The Dow Jones Industrial Average includes many dividend-paying stocks, including many blue-chip companies that have consistently raised their dividends.
Here&#8217;s a look at the top-yielding Dow Jones stocks heading into 2025.
What Happened: The<a href="https://www.benzinga.com/topic/dow-jones-industrial-average"> Dow Jones Industrial Average</a> hit a record high of 45,000 in December as one of many stock indexes to post gains after the 2025 presidential election.
As of Dec. 27, 18 of the Dow Jones Industrial Average stocks have gained year-to-date, while 12 components are trading lower compared to the start of 2024.
While investors can bet on the entire Dow Jones Industrial Average through ETFs like the Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), investors can also pick individual stocks from the 30 components of the index. Through Dec. 27, the ETF is up 13.4% year-to-date.
One popular strategy is to look at the &#8220;Dogs of the Dow,&#8221; which often coincides with the beaten-down stocks of the index that also offer high dividend payouts.
Here are the highest-yielding Dow Jones Industrial Average stocks to start 2025, with the dividend yield and stock performance in 2024 listed below.
<ol>
<li>Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>): 6.79% yield, +5.9% in 2024</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): 4.53% yield, -3.5% in 2024</li>
<li>Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): 3.62% yield, -8.8% in 2024</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): 3.42% yield, -7.5% in 2024</li>
<li>Merck &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): 3.25% yield, -8.5% in 2024</li>
<li>Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): 3.11% yield, +6.0% in 2025</li>
<li>International Business Machines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>): 3% yield, +36.2% in 2024</li>
<li>Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>): 2.68% yield, +18.0% in 2024</li>
<li>McDonald's Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): 2.41% yield, -1.0% in 2024</li>
<li>Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): 2.37% yield, +15.7% in 2024</li>
</ol>
Seven of the top 10 highest-yielding stocks heading into 2025 also appeared on the top 10 list to start 2024 with Merck, McDonald's and Procter &amp; Gamble the newcomers to the Dogs of the Dow list for the new year.
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Williams Addition Could Be More Important</a>
Component Changes Impact Yields: It's worth noting that dividend investors will have to look elsewhere to chase some of the higher-yielding stocks they have become accustomed to.
Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), which yields 10.40% and Dow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>), which yields 6.99% have been replaced and removed from the index.
New 2024 Dow Jones Industrial Average components don't come with high dividend yields. Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) has a dividend yield of 0.80%, NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has a dividend yield of 0.03% and Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) does not pay a dividend.
This means that the yield on ETFs that track the Dow Jones Industrial Average will be lower, with the goal of potentially stronger returns by replacing the underperforming stocks with stocks that have performed better over the past five years.
The latest 30 Dow Jones Industrial Average components see 28 stocks paying out dividends with Amazon and Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) the exceptions.
The average dividend yield of the Dow Jones Industrial Average is around 2%.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent123024" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025

Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 42% bearish. Among these notable options, 9 are puts, totaling $525,048, and 5 are calls, amounting to $288,709.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $245.0 and $320.0 for Amgen, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 139.83 with a total volume of 1,014.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $245.0 to $320.0 over the last 30 days.
<h3>Amgen Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735323335_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$34.8</td>
<td>$34.25</td>
<td>$34.8</td>
<td>$280.00</td>
<td>$191.3K</td>
<td align="right">110</td>
<td align="right">55</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$17.35</td>
<td>$17.3</td>
<td>$17.35</td>
<td>$270.00</td>
<td>$104.0K</td>
<td align="right">18</td>
<td align="right">64</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$24.7</td>
<td>$22.3</td>
<td>$22.8</td>
<td>$310.00</td>
<td>$57.0K</td>
<td align="right">33</td>
<td align="right">28</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$30.85</td>
<td>$30.65</td>
<td>$30.85</td>
<td>$270.00</td>
<td>$52.4K</td>
<td align="right">289</td>
<td align="right">18</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$35.1</td>
<td>$34.5</td>
<td>$34.67</td>
<td>$295.00</td>
<td>$52.0K</td>
<td align="right">97</td>
<td align="right">24</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Amgen's Current Market Status</h3>
<ul>
<li>Trading volume stands at 582,871, with AMGN's price down by -0.55%, positioned at $261.73.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 39 days.</li>
</ul>
<h3>What The Experts Say On Amgen</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $256.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities downgraded its action to Underperform with a price target of $256. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Looking At Amgen's Recent Unusual Options Activity

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$26.50</td>
<td>$152.0K</td>
<td>24.2K</td>
<td>8.7K</td>
</tr>
<tr>
<td>TLRY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.50</td>
<td>$34.6K</td>
<td>54.8K</td>
<td>5.9K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$30.00</td>
<td>$195.0K</td>
<td>6.7K</td>
<td>1.8K</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.50</td>
<td>$41.6K</td>
<td>7.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>AVXL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$17.00</td>
<td>$57.1K</td>
<td>1.5K</td>
<td>1.4K</td>
</tr>
<tr>
<td>LQDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$34.0K</td>
<td>1.8K</td>
<td>93</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$410.00</td>
<td>$28.2K</td>
<td>701</td>
<td>63</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$75.00</td>
<td>$33.4K</td>
<td>94</td>
<td>41</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$275.00</td>
<td>$30.0K</td>
<td>29</td>
<td>24</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$280.00</td>
<td>$26.1K</td>
<td>848</td>
<td>8</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option trade that happens to be bearish, expiring in 1 day(s) on December 27, 2024. This event was a transfer of 8000 contract(s) at a $26.50 strike. The total cost received by the writing party (or parties) was $152.0K, with a price of $19.0 per contract. There were 24292 open contracts at this strike prior to today, and today 8717 contract(s) were bought and sold. 
• Regarding TLRY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on January 17, 2025. Parties traded 1500 contract(s) at a $1.50 strike. This particular call needed to be split into 30 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $23.0 per contract. There were 54857 open contracts at this strike prior to today, and today 5953 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bearish, expiring in 22 day(s) on January 17, 2025. This event was a transfer of 1000 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $195.0K, with a price of $195.0 per contract. There were 6719 open contracts at this strike prior to today, and today 1888 contract(s) were bought and sold. 
• For IOVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>), we notice a call option trade that happens to be bearish, expiring in 22 day(s) on January 17, 2025. This event was a transfer of 757 contract(s) at a $7.50 strike. The total cost received by the writing party (or parties) was $41.6K, with a price of $55.0 per contract. There were 7847 open contracts at this strike prior to today, and today 1775 contract(s) were bought and sold. 
• Regarding AVXL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), we observe a call option sweep with bearish sentiment. It expires in 204 day(s) on July 18, 2025. Parties traded 200 contract(s) at a $17.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $57.1K, with a price of $285.0 per contract. There were 1543 open contracts at this strike prior to today, and today 1410 contract(s) were bought and sold. 
• Regarding LQDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), we observe a call option sweep with bearish sentiment. It expires in 386 day(s) on January 16, 2026. Parties traded 83 contract(s) at a $10.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $34.0K, with a price of $410.0 per contract. There were 1892 open contracts at this strike prior to today, and today 93 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on January 17, 2025. Parties traded 25 contract(s) at a $410.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $1130.0 per contract. There were 701 open contracts at this strike prior to today, and today 63 contract(s) were bought and sold. 
• For TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we notice a put option sweep that happens to be bullish, expiring in 112 day(s) on April 17, 2025. This event was a transfer of 18 contract(s) at a $75.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $33.4K, with a price of $1860.0 per contract. There were 94 open contracts at this strike prior to today, and today 41 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bullish sentiment. It expires in 141 day(s) on May 16, 2025. Parties traded 23 contract(s) at a $275.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $1305.0 per contract. There were 29 open contracts at this strike prior to today, and today 24 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 386 day(s) on January 16, 2026. This event was a transfer of 8 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $3266.0 per contract. There were 848 open contracts at this strike prior to today, and today 8 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AVXL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

LQDA

TLRY

TMDX

VRTX

10 Health Care Stocks With Whale Alerts In Today's Session

Aristotle Value Equity Q4 2024 Commentary

Wells Fargo sees downside to Amgen's (AMGN) 2025 consensus estimates, saying the company' sales guidance could came in below expectations. It model...

Amgen 2025 guidance could miss estimates, says Wells Fargo

How is SCHD stock faring? The Schwab U.S. Dividend Equity ETF is up 1.17% in the past five days and has risen 14.16% over the past year.  According...

SCHD ETF News, 1/22/2025

How To Invest $100,000 In The Ten Cheapest Dow Dividend 100 Stocks

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT – Research Report), Arrowhe...

Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Arrowhead Pharmaceuticals (ARWR)

Allurion stock soars 70% on weight-loss therapy update

DIVO: Hard To Create A Case For Income Investors, Who Seek Covered-Call Exposure

Janux Therapeutics (JANX) announced the promotion of Dr. Zachariah McIver to Chief Medical Officer. Dr. McIver joined Janux after serving as Amgen'...

Janux Therapeutics names Zachariah McIver, D.O., Ph.D. as Chief Medical Officer

What Moved Markets This Week

5 Best CEFs This Month For Nearly 10% Yield (January 2025)

ADBE

ALUR

AMSF

ARWR

BANX

BMYMP

CBRL

COST

DINO

DIVO

EXPE

FEPI

FSLR

GOOGL

GPCR

JANX

JBHT

JEPI

JEPQ

MCHP

MRNA

MSFT

MUFG

NFLX

NXST

ORCL

PAYX

PLTR

QQQX

RHHBY

RILY

RILYL

TERN

TSLA

VKTX

XFLT

ZLDPF

Press Releases

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY

AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE

AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE

AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA

BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND

Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer

AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

deCODE genetics: Complete recombination map of the human-genome, a major step in genetics

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

RBC Capital

Wells Fargo

Truist Securities

Piper Sandler

B of A Securities

시장이 불안정하고 혼란스러운 시기에는 많은 투자자들이 배당 수익률이 높은 주식으로 눈을 돌린다. 이러한 주식은 높은 잉여 현금 흐름을 가지고 있으며 주주들에게 높은 배당금을 지급하여 보상을 한다.
벤징가 독자들은 <a href="https://www.benzinga.com/analyst-stock-ratings">애널리스트 주식 등급</a> 페이지를 방문하여 자신이 선호하는 주식에 대한 최신 애널리스트 의견을 검토할 수 있다. 트레이더들은 벤징가의 방대한 애널리스트 등급 데이터베이스를 필터링하여 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">애널리스트 정확도</a>에 따라 정렬할 수 있다.
아래는 의료 부문에서 배당 수익률이 높은 세 개의 주식에 대한 가장 정확한 애널리스트들의 평가이다.
<h3 class="wp-block-heading">암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</h3>
<ul>
<li>배당 수익률: 3.67%</li>
<li>파이퍼 샌들러의애널리스트 데이비드 암셀렘(David Amsellem)은 1월 2일 주식에 대해 비중 확대 등급을 유지하고 목표 주가를 $344에서 $310으로 하향 조정했다. 이 애널리스트의 정확도는 66%이다.</li>
<li>BofA 증권의애널리스트 팀 앤더슨(Tim Anderson)은 12월 10일 주식에 대해 언더퍼폼 등급을 재부여하고 목표 주가를 $256로 설정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>최근 뉴스: 암젠은 12월 10일 1분기 배당금을 주당 $2.25에서 $2.38로 6% 인상했다.</li>
<li>Benzinga Pro의 실시간 뉴스 피드에서 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">최신 AMGN 뉴스를</a> 알림 받았다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716759" style="width: 619px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png" sizes="(max-width: 902px) 100vw, 902px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-768x705.png 768w" alt="" width="902" height="828" /></a></figure>
<h3 class="wp-block-heading">애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>배당 수익률: 3.66%</li>
<li>BofA 증권의애널리스트 팀 앤더슨(Tim Anderson)은 12월 10일 주식에 대해 중립 등급을 재부여하고 목표 주가를 $191로 설정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>리링크 파트너스의 애널리스트 데이비드 라이징거(David Risinger)는 11월 22일 주식을 시장 평균에서 아웃퍼폼으로 상향 조정하고 목표 주가를 $206으로 설정했다. 이 애널리스트의 정확도는 75%이다.</li>
<li>최근 뉴스: 애브비는 12월 13일 님블 테라퓨틱스(Nimble Therapeutics)를 인수할 계획을 발표했다.</li>
<li>Benzinga Pro의 실시간 뉴스 피드에서 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">최신 ABBV 뉴스를</a> 알림 받았다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716760" style="width: 670px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png" sizes="(max-width: 917px) 100vw, 917px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-768x709.png 768w" alt="" width="917" height="847" /></a></figure>
<h3 class="wp-block-heading">CVS 헬스 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>배당 수익률: 6.02%</li>
<li>도이치 뱅크의 애널리스트 조지 힐(George Hill)은 12월 3일 주식을 보유에서 매수로 상향 조정하고 목표 주가를 $66으로 설정했다. 이 애널리스트의 정확도는 60%이다.</li>
<li>트루이스트 증권의 애널리스트 데이비드 맥도날드(David Macdonald)는 11월 20일 주식에 대해 매수 등급을 재확인하고 목표 주가를 $76에서 $67로 하향 조정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>최근 뉴스: 최근 법무부(DOJ)는 CVS가 2013년부터 불법 처방전으로 오피오이드 조합약과 과다량을 조제하여 관리 약물 법을 위반했다고 주장했다.</li>
<li>Benzinga Pro의 차트 도구가 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">CVS 주식의 추세</a>를 식별하는 데 도움을 주었다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716761" style="width: 584px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png" sizes="(max-width: 912px) 100vw, 912px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-768x712.png 768w" alt="" width="912" height="845" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio">
<div class="wp-block-embed__wrapper"><iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&amp;feature=oembed" width="500" height="281" frameborder="0" allowfullscreen="allowfullscreen"></iframe></div>
</figure>
더 읽기:
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">애큐티 브랜드 주식으로 월 $500를 버는 방법</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

주식과 옵션을 볼 때 투자자들은 섹터 회전, 실적 강세, 다가오는 촉매제 등 여러 가지 전략을 사용한다. 가치 투자자들은 종종 <a href="https://www.benzinga.com/topic/dividend-stocks">배당주에서</a> 강력한 실적 강세를 찾는다.
다우존스 산업평균지수에는 배당금을 지급하는 주식이 많이 포함되어 있으며, 꾸준히 배당금을 인상해 온 블루칩 기업들이 많다.
2025년을 맞이하기 앞서, 다우존스의 고수익 주식들을 살펴보겠다.
무슨 일이 있었나: 다우존스 산업평균지수는 2025년 대통령 선거 이후 여러 주식 지수가 상승세를 보인 가운데 12월에 45,000으로 사상 최고치를 기록했다.
12월 27일 기준으로, 다우존스 산업평균지수의 주식 18개가 연초 대비 상승했으며, 12개 구성 종목은 2024년 초와 비교하여 하락세를 보이고 있다.
투자자들은 다우존스 산업평균지수 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)를 통해 전체 다우존스 산업평균지수에 투자할 수 있지만, 지수의 30개 구성 종목 중 개별 주식을 선택할 수도 있다. 12월 27일 기준으로 ETF는 연초 대비 13.4% 상승했다.
인기 있는 전략 중 하나는 &#8220;다우의 개(Dogs of the Dow)&#8221; 주식에 주목하는 것이며, 이는 종종 배당금 지급률이 높은 하락세를 보이는 주식과 일치한다.
&#x2A;&#x2A; 다우의 개: 다우존스 지수를 추종하는 강아지라는 의미.
2025년을 시작하기 위해 가장 높은 수익률을 기록한 다우존스 산업평균지수의 주식들이 아래와 같이 정리되어 있다. 배당 수익률과 2024년 주식 실적이 나열되어 있다.
<ol>
<li>버라이즌 커뮤니케이션스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>): 6.79% 수익률, 2024년 +5.9%</li>
<li>쉐브론 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): 4.53% 수익률, 2024년 -3.5%</li>
<li>암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): 3.62% 수익률, 2024년 -8.8%</li>
<li>존슨앤드존슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): 3.42% 수익률, 2024년 -7.5%</li>
<li>머크 앤드 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): 3.25% 수익률, 2024년 -8.5%</li>
<li>코카콜라 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): 3.11% 수익률, 2025년 +6.0%</li>
<li>IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>): 3% 수익률, 2024년 +36.2%</li>
<li>시스코 시스템즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>): 2.68% 수익률, 2024년 +18.0%</li>
<li>맥도날드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): 2.41% 수익률, 2024년 -1.0%</li>
<li>프록터 앤드 갬블 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): 2.37% 수익률, 2024년 +15.7%</li>
</ol>
2025년을 맞이하여 가장 높은 수익률을 기록한 주식 10개 중 7개가 2024년 초에도 상위 10개 주식 목록에 올라 있었으며, 머크, 맥도날드 및 프록터 앤드 갬블이 새롭게 다우의 개 주식 목록에 오른 것으로 나타났다.
또한 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84%EA%B0%80-%EB%8B%A4%EC%9A%B0%EC%A1%B4%EC%8A%A4-%EC%A7%80%EC%88%98%EC%97%90-%ED%95%A9%EB%A5%98-%EC%A7%80%EC%88%98%EC%97%90%EC%84%9C-%EC%96%B4%EB%96%A4-%EC%88%9C/" target="_blank" rel="noopener">엔비디아가 다우존스 산업평균지수에 포함된 것: 기술 대기업이 지수에서 차지하는 위치, 셔윈-윌리엄스 추가가 더 중요한 이유</a>
구성 변경이 수익률에 미치는 영향: 배당 투자자들은 그들이 익숙해진 높은 수익률의 주식들을 찾기 위해 다른 곳을 찾아야 할 것이다.
10.40%의 수익률을 제공하 월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)와 6.99%의 수익률을 주는 다우(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)가 지수에서 교체되어 제외되었다.
2024년 새로운 다우존스 산업평균지수 구성 종목들은 높은 배당 수익률을 제공하지 않다. 셔윈-윌리엄스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>)는 0.80%의 배당 수익률, 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 0.03%의 배당 수익률, 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)은 배당금을 지급하지 않는다.
이는 다우존스 산업평균지수를 추적하는 ETF의 수익률이 낮아질 것을 의미하며, 과거 5년 동안 실적이 좋았던 주식으로 하락세를 보인 주식을 교체하여 더 강한 수익률을 추구하는 것이 목표이다.
최신 30개 다우존스 산업평균지수 구성 종목 중 28개 주식은 배당금을 지급하며, 아마존과 보잉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)은 예외이다.
다우존스 산업평균지수의 평균 배당 수익률은 약 2%이다.
알고 계셨나요?
<ul>
<li>의회가 대규모 투자를 하고 있습니다.  <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent123024" target="_blank" rel="noreferrer noopener">2024년 선거를 앞두고 그들이 무엇을 사고 팔았는지 쉽게 확인할 수 있는 도구로 알아보세요</a></li>
</ul>
사진 출처: Shutterstock


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

슈왑 미국 배당주 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>)는 12월에 7% 이상 하락하면서 지난 한 달 동안 1년간 상승폭의 절반 이상을 반납했다. <a href="https://www.benzinga.com/24/12/42528079/this-high-yield-dividend-etf-is-undergoing-a-harsh-reversal-signaling-bearish-trends-here-what-you-need-to-know" target="_blank" rel="noopener">SCHD 펀드가 하락한 이유를 살펴보자.</a>
알아야 할 내용: 슈왑 미국 배당주 ETF는 4개의 제약주가 펀드 전체 보유 자산의 15.83%를 차지해 헬스케어 부문에 큰 비중을 두고 있다. 헬스케어 섹터는 최근 도널드 트럼프 대통령 당선인의 행정부 책임자 임명 및 <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" target="_blank" rel="noopener">정책 변화</a>에 대한 불확실성이 높아지면서 실적이 저조했다.
<h2>헬스케어 부문 보유 종목</h2>
브리스톨 마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 펀드 내에서 가장 큰 제약 보유 종목으로, 자산의 4.64%를 차지한다. 지난 한달 동안 주가는 2.6% 하락했다.
화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)도 펀드의 상위 10개 보유 종목에 속흔다. 백신 제조사 화이자는 앞으로 불확실한 정치 및 규제 환경에 직면하면서 대선 이후 5% 이상 하락했다.
애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)도 헬스케어 보유 종목이다. 애브비 주가는 소폭 하락했지만 암젠 주가는 12월에 체중 감량 약물 후보인 마리타이드(MariTide)의 실망스러운 <a href="https://www.benzinga.com/content/42377651/amgen-stock-falls-on-weight-loss-drug-data-overreaction-or-fair" target="_blank" rel="noopener">임상시험 </a>결과로 인해 10% 이상 하락했다.
금리: 슈왑 미국 배당주 ETF에 영향을 미칠 수 있는 또 다른 요인은 불확실한 금리 환경이다. 저금리 환경에서는 배당금이 투자자에게 더 매력적으로 다가오는 경향이 있다. 최근 연준의 발언에 따르면 인플레이션이 연준의 목표 금리인 2%를 상회하는 등 매파적인 전망이 나온다.
또한 트럼프가 해외 수입품에 대한 관세를 인상하겠다고 공약한 만큼 차기 트럼프 행정부가 인플레이션을 재점화하고 금리를 더 오래 유지할 수 있는 요인으로 작용할 수 있다.
금리가 높으면 채권 및 기타 채권형 증권의 수익률 경쟁이 치열해져 배당 수익률은 상대적으로 매력도가 떨어지게 된다.
이미지: Shutterstock
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%EC%A3%BC%EA%B0%80-4-%EA%B0%80%EA%B9%8C%EC%9D%B4-%EC%83%81%EC%8A%B9%ED%95%9C-%EC%9D%B4%EC%9C%A0%EB%8A%94/" target="_blank" rel="noopener">엔비디아, 주가 4% 가까이 상승한 이유는?</a>
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Amgen

뉴스

에 대한 최신 뉴스 Amgen (NASDAQ:AMGN) 주식

토요일, 1월 04, 2025

수요일, 1월 01, 2025

화요일, 12월 24, 2024

금요일, 11월 22, 2024

월요일, 11월 18, 2024

수요일, 11월 13, 2024

금요일, 10월 11, 2024

일요일, 7월 07, 2024

목요일, 7월 04, 2024

월요일, 5월 06, 2024

금요일, 5월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌